EZH2 and systemic lupus erythematosus: MRL/lpr mice treated with EZH2 inhibitors exhibit lowered anti-dsDNA antibodies, decreased inflammatory cytokines, improved symptoms, and reduced mortality, indicating that EZH2 is a promising therapeutic target for lupus.